Insmed INSM Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 313.8%+5.3pp | 308.5%+3.3pp | 305.2%-0.7pp | 305.9%-1.9pp | 307.8%-1.6pp | |
| Operating margin | -857.5%+117pp | -974.4%+35.9pp | -1,010.2%-18.0pp | -992.2%-21.0pp | -971.2%-33.3pp | |
| Net margin | -879.6%+121pp | -1,001.1%+40.7pp | -1,041.8%-12.8pp | -1,029%-15.5pp | -1,013.4%-29.2pp | |
| EBITDA margin | -846.4%+116pp | -962.5%+35.6pp | -998.1%-17.8pp | -980.3%-20.4pp | -959.8%-32.6pp | |
| Free cash flow margin | -692.9%+94.7pp | -787.6%+34.5pp | -822.1%-17.3pp | -804.8%-38.4pp | -766.4%-20.6pp | |
| Returns | ||||||
| Return on equity | -870%— | —— | —— | —— | —— | |
| Return on assets | -222.4%+7.4pp | -229.8%-5.1pp | -224.8%-2.5pp | -222.3%+1.2pp | -223.5%-12.6pp | |
| Return on invested capital | -766%+48.9pp | -814.9%-8.5pp | -806.4%+9.7pp | -816.1%-10.2pp | -805.9%+242pp | |
| Efficiency | ||||||
| Asset turnover | 1.1×+0.2× | 0.9×+0.1× | 0.9×0.0× | 0.9×0.0× | 0.9×0.0× | |
| Inventory turnover | 4.3×+0.3× | 4×+0.1× | 3.9×+0.1× | 3.8×+0.1× | 3.7×+0.1× | |
| Liquidity | ||||||
| Current ratio | 19.6×-1.4× | 21×-1.6× | 22.6×-1.7× | 24.4×+4.0× | 20.4×+4.1× | |
| Quick ratio | 18.3×-1.3× | 19.7×-1.6× | 21.2×-1.6× | 22.9×+3.8× | 19.1×+3.8× | |
| Cash ratio | 7.6×-0.1× | 7.7×-0.8× | 8.5×-1.0× | 9.5×+1.7× | 7.7×+0.3× | |
| Leverage | ||||||
| Debt-to-equity | 2.7×-10.7× | 13.4×-3.2× | 16.6×-1.5× | 18.1×-30.9× | 49×— | |
| Debt-to-assets | 1×-0.4× | 1.4×-0.3× | 1.7×-0.2× | 1.9×-0.4× | 2.4×-0.4× | |
| Interest coverage | -54.3×-2.5× | -51.8×-4.5× | -47.2×-3.8× | -43.4×-2.6× | -40.8×-2.9× | |
| Per Share | ||||||
| Book value per share | $18.05+17.8% | $15.33+14.8% | $13.36+14.4% | $11.67+119% | $5.32+224% | |
| Valuation | ||||||
| Market capitalization | $122.92B+21.1% | $101.48B+32.3% | $76.72B+33.3% | $57.57B+21.5% | $47.4B+26.3% | |
| Enterprise value | $122.53B+20.3% | $101.83B+31.3% | $77.59B+32.1% | $58.74B+19.3% | $49.25B+25.5% | |
| Price / sales | 222.8×+6.8× | 216.1×+27.2× | 188.8×+35.2× | 153.7×+20.3× | 133.4×+23.8× | |
| Price / book | 148.5×-89.2× | 237.8×+6.9× | 230.8×+8.8× | 222×-240× | 462.1×— | |
| EV / sales | 221.7×+4.8× | 216.9×+25.7× | 191.2×+34.1× | 157×+18.6× | 138.5×+23.8× | |
| Free cash flow yield | -12.5%+3.1pp | -15.6%+3.1pp | -18.7%+2.7pp | -21.4%+1.6pp | -23%+9.3pp | |
| Earnings yield | -15.8%+4.0pp | -19.8%+4.0pp | -23.8%+3.8pp | -27.5%+2.9pp | -30.5%+11.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Insmed's profit margins?
- Insmed (INSM) runs a 81.8% gross margin and a -140.6% operating margin, with a -144.4% net margin.
- Where do Insmed's ratios come from?
- Every ratio is computed from Insmed's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
